General Information
Viking NASH VK2809-201
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Vk2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients with Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
| Protocol | VK2809-201 |
|---|---|
| Identifier | |
| UID | 1232687e-fb5c-485d-8fa6-0d90524512a5 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Fatty Liver / Adult |
| Launch Year | 2017 |
| NCT Number | - |
| Created | 2016-12-15 11:51 |
| Last Updated | 2016-12-15 11:51 |
Description
No description provided.
Comment
PCRS
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2018-10-05 | No |
| Enrollment Open | 2017-02-02 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2017-01-25 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2019-05-09 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Viking |
|---|---|
| Division | Viking |
| Team | Viking |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Integrium Clinical Research |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
